Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Regains Nasdaq Compliance, Escapes Delisting

NEW YORK, Sept. 19 (GenomeWeb News) - Transgenomic will continue to be listed on the Nasdaq after its share price closed at or above $1 for 10 consecutive business days, the company said today.

 

In March, Transgenomic was notified by the Nasdaq exchange that it had not maintained the mimimum closing bid price of $1 for 30 consecutive trading days and was therefore in danger of being delisted from the Nasdaq National Market. The company had until Sept. 27 to regain compliance.

 

According to CEO Collin D'Silva, recent changes of the company's business resulted in improved financial results and the increase in share price.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.